In the global landscape, approximately 7,000 rare diseases have been identified. In Colombia, the Ministry of Health has registered 2,236 diagnoses of this type. These conditions, often referred to as orphan diseases, affect a small number of people compared to other health conditions. Importantly, although many of these diseases are of genetic origin, others can be of infectious, autoimmune, oncological origin, or their cause may be unknown.

Two out of every three rare disease cases are diagnosed in childhood, with 39% of cases affecting individuals between 0 and 24 years old. Additionally, 57.2% of these diseases affect women, highlighting the significant gender disparities in health outcomes.

Officially Recognized Rare Diseases

The official database for orphan diseases in Colombia, known as the National Registry of Patients with Rare Diseases, lists 84,175 people diagnosed with these conditions. However, these individuals confront substantial barriers to accessing innovative treatments that could significantly improve their quality of life.

Logistics and geographical obstacles make it particularly challenging for rural patients. They frequently endure long journeys to specialized treatment centers or manage complicated medication storage requirements, ” said Dr. Andrés Pérez, medical manager of Novo Nordisk in Colombia.

Dr. Pérez’s explains,

“Access remains one of the main challenges in Colombia. Although innovative treatments are available, infrastructure and distribution difficulties remain critical barriers so that all patients can benefit from them.”

Patients in rural areas of the United States and Colombia often face similar difficulties. For instance, because of limited medical facilities, Medicare patients in the South often endure longer wait times and further travel distances for specialized healthcare than those in urban centers.

Dr. Pérez also emphasized the importance of primary care, noting,

“All patients with rare diseases should continue their attention within its primary health network since they can be affected by other comorbidities of their age or risk group, throughout life.”

Primary Care and Innovation

Pérez also highlighted the urgent need for research and development within the country. Innovation in orphan diseases has grown significantly in recent years, with the introduction of biotechnological and personalized treatments that can transform patients’ lives.

The scientific community advocates for more cooperative efforts between federal and state governments to provide better accessibility for these treatments. This could resemble the network of comprehensive primary care centers in the United States, which connect these vulnerable patients with specialized services in hospital districts, enabling them to potentially travel shorter distances and enhance patient care.

The emphasis on primary care integration reflects a growing global trend. Health systems around the world, including those in the U.S. and Colombia, are increasingly adopting holistic approaches, whereby expert and community-centered care is reinforced through health professionals and well-automated facilities.

Raising Demand for Care

From a demographic perspective, 48.1% of people with orphan diseases reside in the three largest health districts in Colombia: Antioquia (19,926), Valle de Cauca (10,832), and Bogotá (9,689). Additional 38.5% reside in other major cities and nearly 13.2% in rural regions.

“There’s a similar disparity in the U.S., where rural populations often struggle with access to specialized care due to the scarcity of healthcare professionals and treatment centers,” said another medical expert in the same space.

Dr. Pérez concluded,

“Access to innovative treatments is a key element to improving the quality of life of patients with orphan diseases. It is essential to strengthen cooperation between the public and private sectors to ensure that these therapies reach those who need them most.”

Considering the substantial barriers to access treatments for rare afflictions in both nations, implementing such public-header interorganizational collaborative measures would not only significantly improve health accessibility to these vulnerable communities but also promote abundant economic growth in both nations.